

1  
2  
3  
4  
5  
6  
7  
8  
9  
  
10  
11  
  
12  
13  
14  
15  
16  
17

H.278

Introduced by Representatives Dickinson of St. Albans Town and Savage of  
Swanton

Referred to Committee on

Date:

Subject: Health; prescription drugs; prescribed product manufacturers; gift ban

Statement of purpose of bill as introduced: This bill proposes to exempt items  
of nominal value and certain employees of health care practitioners from  
Vermont's prescribed product manufacturer gift ban.

An act relating to exemptions to Vermont's prescribed product  
manufacturer gift ban

It is hereby enacted by the General Assembly of the State of Vermont:

Sec. 1. 18 V.S.A. § 4631a is amended to read:

§ 4631a. EXPENDITURES BY MANUFACTURERS OF PRESCRIBED  
PRODUCTS

(a) As used in this section:

\* \* \*

1 (5) “Gift” means:

2 (A) Anything of value provided for free to a health care provider or  
3 to a member of the Green Mountain Care ~~board~~ Board established in chapter  
4 220 of this title; or

5 (B) Except as otherwise provided in subdivision (a)(1)(A)(ii) of this  
6 section, any payment, food, entertainment, travel, subscription, advance,  
7 service, or anything else of value provided to a health care provider or to a  
8 member of the Green Mountain Care ~~board~~ Board established in chapter 220 of  
9 this title, unless:

10 (i) it is an allowable expenditure as defined in subdivision (a)(1)  
11 of this section; or

12 (ii) the health care provider or ~~board~~ Board member reimburses  
13 the cost at fair market value.

14 (6) “Health benefit plan administrator” means the person or entity who  
15 sets formularies on behalf of an employer or health insurer.

16 (7)(A) “Health care professional” means:

17 (i) a person who is authorized by law to prescribe or to  
18 recommend prescribed products, who regularly practices in this ~~state~~ State, and  
19 who either is licensed by this ~~state~~ State to provide or is otherwise lawfully  
20 providing health care in this ~~state~~ State; or

1 (ii) a partnership or corporation made up of the persons described  
2 in subdivision (i) of this subdivision (7)(A); ~~or~~

3 ~~(iii) an officer, employee, agent, or contractor of a person~~  
4 ~~described in subdivision (i) of this subdivision (7)(A) who is acting in the~~  
5 ~~course and scope of employment, of an agency, or of a contract related to or~~  
6 ~~supportive of the provision of health care to individuals.~~

7 (B) The term shall not include a person described in subdivision (A)  
8 of this subdivision (7) who is employed solely by a manufacturer.

9 (8) "Health care provider" means a health care professional, hospital,  
10 nursing home, pharmacist, health benefit plan administrator, or any other  
11 person authorized to dispense or purchase for distribution prescribed products  
12 in this ~~state~~ State. The term does not include a hospital employee, other than a  
13 purchasing agent, without the authority to prescribe or recommend prescribed  
14 products or a hospital foundation that is organized as a nonprofit entity  
15 separate from a hospital.

16 \* \* \*

17 (b)(1) It is unlawful for any manufacturer of a prescribed product or any  
18 wholesale distributor of medical devices; or any agent thereof; to offer or give  
19 any gift to a health care provider or to a member of the Green Mountain Care  
20 ~~board~~ Board established in chapter 220 of this title.



1                   (iii) ~~payments~~ Payments for clinical trials as described in  
2                   subdivision 4631a(a)(1)(C) of this title, which shall be disclosed after the  
3                   earlier of the date of the approval or clearance of the prescribed product by the  
4                   Food and Drug Administration for the use for which the clinical trial is being  
5                   conducted or four calendar years after the date the payment was made. For a  
6                   clinical trial for which disclosure is delayed under this subdivision (iii), the  
7                   manufacturer shall identify to the ~~attorney general~~ Attorney General the  
8                   clinical trial, the start date, and the web link to the clinical trial registration on  
9                   the national clinical trials registry;

10                   (iv) ~~interview~~ Interview or health care expenses as described in  
11                   subdivision 4631a(a)(1)(G) of this title;

12                   (v) ~~coffee~~ Coffee or other snacks or refreshments at a booth at a  
13                   conference or seminar;

14                   (vi) ~~loans~~ Loans of medical devices for short-term trial periods  
15                   pursuant to subdivision 4631a(b)(2)(B) of this title, provided the loan results in  
16                   the purchase, lease, or other comparable arrangement of the medical device  
17                   after issuance of a certificate of need pursuant to chapter 221, subchapter 5 of  
18                   this title; ~~and~~

19                   (vii) ~~prescribed~~ Prescribed products distributed free of charge or at  
20                   a discounted price pursuant to a manufacturer-sponsored or manufacturer-  
21                   funded patient assistance program.

1                    (viii) Items of nominal value, as defined by the Attorney General  
2 by rule.

3                    (B) Annually on or before April 1 of each year, every manufacturer  
4 of prescribed products shall disclose to the ~~office of the attorney general~~ Office  
5 of the Attorney General for the preceding calendar year if the manufacturer is  
6 reporting other allowable expenditures or permitted gifts pursuant to  
7 subdivision (a)(1)(A) of this section; the product, dosage, number of units, and  
8 recipient information of over-the-counter drugs, nonprescription medical  
9 devices, items of nonprescription durable medical equipment, medical food,  
10 and infant formula provided to a health care provider for free distribution to  
11 patients pursuant to subdivision 4631a(b)(2)(A) of this title; provided that any  
12 public reporting of such information shall not include information that allows  
13 for the identification of individual recipients of such products or connects  
14 individual recipients with the monetary value of the products provided.

15                    (C) Annually on or before April 1 of each year, every manufacturer  
16 of prescribed products shall disclose to the ~~office of the attorney general~~ Office  
17 of the Attorney General for the preceding calendar year the value, nature,  
18 purpose, and recipient information of any allowable expenditure or gift to an  
19 academic institution, to a nonprofit hospital foundation, or to a professional,  
20 educational, or patient organization representing or serving health care

1 providers or consumers located in or providing services in Vermont, except for  
2 the following :

3 (i) ~~royalties~~ Royalties and licensing fees as described in  
4 subdivision 4631a(a)(1)(F) of this title;

5 (ii) ~~rebates~~ Rebates and discounts for prescribed products  
6 provided in the normal course of business as described in subdivision  
7 4631a(b)(2)(F) of this title; ~~and~~.

8 (iii) ~~payments~~ Payments for clinical trials as described in  
9 subdivision 4631a(a)(1)(C) of this title, which shall be disclosed after the  
10 earlier of the date of the approval or clearance of the prescribed product by the  
11 Food and Drug Administration for the use for which the clinical trial is being  
12 conducted or four calendar years after the date the payment was made. For a  
13 clinical trial for which disclosure is delayed under this subdivision (iii), the  
14 manufacturer shall identify to the ~~attorney general~~ Attorney General the  
15 clinical trial, the start date, and the web link to the clinical trial registration on  
16 the national clinical trials registry.

17 (iv) Items of nominal value, as defined by the Attorney General by  
18 rule.

19 (D) Any public reporting of the provision of free prescription or  
20 over-the-counter drugs, medical devices, biological products, medical  
21 equipment, combination products, medical food, infant formula, or supplies to

1 a free clinic shall not include information that allows for the identification of  
2 individual recipients of such products or that connects individual recipients  
3 with the monetary value of the products provided.

4 \* \* \*

5 Sec. 3. EFFECTIVE DATE

6 This act shall take effect on July 1, 2013.